<DOC>
	<DOCNO>NCT01133353</DOCNO>
	<brief_summary>The purpose clinical trial study therapeutic effect tetrabenazine MR child Tourette 's Syndrome , measure improvement total tic score Yale Global Tic Severity Scale ( YGTSS ) .</brief_summary>
	<brief_title>A Study Effectiveness Safety Tetrabenazine MR Pediatric Subjects With Tourette 's Syndrome</brief_title>
	<detailed_description>Tourette 's Syndrome ( TS ) typically diagnose early childhood ( 6-7 year ) age 21 year characterize chronic , intermittent motor phonic tic . There body evidence , mostly clinical experience data , suggest efficacy tetrabenazine TS patient tic , include patient unresponsive treatment option . These publication consistently report usefulness tetrabenazine alternative conventional neuroleptic treatment TS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Tourette Syndrome</mesh_term>
	<mesh_term>Tetrabenazine</mesh_term>
	<criteria>Subjects must meet following criterion : 1 . Children age 5 17 year 2 . Subjects must capable provide informed consent assent , applicable , parents/legal guardian must capable provide informed consent/permission comply study procedure 3 . Subject parents/legal guardian must able communicate effectively Investigator study coordinator 4 . Diagnosed Tourette 's Syndrome , accord DSMIVTR use KSADSPL aid diagnosis , require drug therapy 5 . Total tic score ≥ 22 measure YGTSS screen baseline 6 . Total body weight ≥ 15 kg ( 33 lb . ) 7 . Tics cause distress impairment , determine parent/legal guardian subject Investigator , despite current treatment regimen 8 . Able swallow whole tablet without difficulty 9 . Nonpregnant status : All female subject must nonpregnant ( demonstrated negative serum βHCG test ) , nonbreastfeeding , must avoid pregnancy least 10 day sign informed consent/assent 1 month end study abstain sexual activity use two ( 2 ) medically acceptable method contraception , : nonhormonal IUD spermicide , female condom spermicide , contraceptive sponge spermicide , intravaginal system , diaphragm spermicide , cervical cap spermicide , male sexual partner agree use male condom spermicide , sterile sexual partner . Male subject must abstain sexual activity time sign inform consent/assent 1 month end study use condom spermicide . For female child bear potential , serum pregnancy test result must negative Screening urine pregnancy test must negative Baseline Subjects eligible follow criterion meet : 1 . Subjects history current major depressive disorder 2 . Prior treatment &gt; 7 dos tetrabenazine 3 . Prior treatment reserpine 4 . Subjects impaired renal function ( defined creatinine level ≥ 1.5 time upper limit ageappropriate normal value ) 5 . Subjects current history suicidal ideation 6 . Participation investigational medication trial within 3 month prior Screening visit , except study BVF018102 7 . Use Botox® ( botulinum toxin ) within 4 month prior Screening visit 8 . Immediate family site Investigators sponsor employee 9 . Excluding condition relate directly disease study , subject history presence clinically significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , oncologic condition , opinion Investigator , would jeopardize safety subject validity study result . 10 . Subjects clinically important thyroid dysfunction require medication 11 . Subjects impaired hepatic function ( define SGOT/SGPT level ≥ 1.5 time upper limit ageappropriate normal value ) 12 . Subjects Children 's Depression Rating ScaleRevised ( CDRSR ) total score &gt; 65 13 . Male subject QTc &gt; 450 msec ; female subject QTc &gt; 470 msec base Bazzett 's correction formula 14 . Organic brain disease , example , traumatic brain injury residuum toxic delirium 15 . Any subject immediate risk require hospitalization 16 . Physical examination , electrocardiography , laboratory value clinically important opinion Investigator 17 . Autistic spectrum disorder 18 . Schizophrenia 19 . Other psychotic disorder 20 . Subjects Bipolar I Disorder 21 . Subjects one firstdegree relatives Bipolar I Disorder 22 . Subjects unable complete washout period 4 week fluoxetine 3 week MAOIs , respectively , prior Baseline visit require fluoxetine MAOIs Treatment Period 23 . Inability washout strong inhibitor inducer CYP2D6 within 7 day Baseline visit 24 . Positive finding urine drug screen Screening Visit 25 . Allergies tetrabenazine excipients</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>